It's true that we are 2% of the world market, but that's not a negligible amount. That makes us a top 10 market, so it's not surprising that we would account for a significant amount of clinical trial development. I will say that pharmaceutical patentees, from the industry, account for a small minority of those clinical trials in Canada. They are the exception. It's mostly other organizations within the health care system that conduct those clinical trials.
I can't say that you reduce the price to this or that amount and it will equal this or that number of clinical trials. I just don't think there's a formula that lands you there magically. All I can say is that we are unable to discern a strong correlation between price and clinical trial intensity. In fact, we see the opposite.